Savara Inc. Stock
Price
Target price
€4.86
€4.86
0.840%
0.04
0.840%
€8.00
16.04.24 / Tradegate
WKN: A2DQ2B / Symbol: MSTX / Name: Savara / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Savara Inc. Stock
The Savara Inc. stock is trending slightly upwards today, with an increase of €0.040 (0.840%) compared to yesterday's price.
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Savara Inc. stock is not clear.
With a target price of 8 € there is a hugely positive potential of 64.61% for Savara Inc. compared to the current price of 4.86 €.
So far the community has only identified positive things for Savara Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Savara Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Savara Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Savara Inc. | 0.840% | 9.955% | 8.000% | 192.771% | 13.551% | 247.143% | -41.481% |
| Rockwell Medical Inc. | 2.380% | -6.480% | 9.890% | -28.205% | -21.437% | -84.031% | -96.909% |
| Gritstone Oncology Inc | 0.210% | -18.757% | -69.521% | -70.915% | -62.352% | -90.305% | - |
| Innoviva Inc. | 0.740% | 0.730% | 2.985% | 32.692% | -5.479% | 40.102% | - |
News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending